Eli Lilly And Co (NYSE:LLY) Shares Sold by Fort Washington Investment Advisors Inc. OH

Fort Washington Investment Advisors Inc. OH lowered its stake in Eli Lilly And Co (NYSE:LLY) by 12.1% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 32,459 shares of the company’s stock after selling 4,460 shares during the quarter. Fort Washington Investment Advisors Inc. OH’s holdings in Eli Lilly And Co were worth $4,212,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the company. Trust Department MB Financial Bank N A increased its stake in Eli Lilly And Co by 54.7% during the 1st quarter. Trust Department MB Financial Bank N A now owns 232 shares of the company’s stock valued at $30,000 after purchasing an additional 82 shares in the last quarter. Captrust Financial Advisors increased its stake in Eli Lilly And Co by 0.4% during the 4th quarter. Captrust Financial Advisors now owns 21,627 shares of the company’s stock valued at $2,503,000 after purchasing an additional 87 shares in the last quarter. Bronfman E.L. Rothschild L.P. increased its stake in Eli Lilly And Co by 1.6% during the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 5,543 shares of the company’s stock valued at $641,000 after purchasing an additional 87 shares in the last quarter. Bailard Inc. increased its stake in Eli Lilly And Co by 3.6% during the 4th quarter. Bailard Inc. now owns 2,672 shares of the company’s stock valued at $309,000 after purchasing an additional 92 shares in the last quarter. Finally, Wealthquest Corp increased its stake in Eli Lilly And Co by 1.5% during the 1st quarter. Wealthquest Corp now owns 6,307 shares of the company’s stock valued at $818,000 after purchasing an additional 94 shares in the last quarter. Institutional investors own 79.42% of the company’s stock.

LLY has been the subject of a number of recent research reports. BMO Capital Markets boosted their price target on shares of Eli Lilly And Co from $130.00 to $133.00 and gave the company an “outperform” rating in a research note on Wednesday, May 1st. Bank of America set a $129.00 target price on shares of Eli Lilly And Co and gave the stock a “hold” rating in a research note on Thursday, March 21st. Citigroup set a $124.00 target price on shares of Eli Lilly And Co and gave the stock a “hold” rating in a research note on Tuesday, February 26th. UBS Group started coverage on shares of Eli Lilly And Co in a research note on Wednesday, March 20th. They issued a “buy” rating and a $74.51 target price for the company. Finally, JPMorgan Chase & Co. started coverage on shares of Eli Lilly And Co in a research note on Tuesday, March 12th. They issued an “overweight” rating and a $140.00 target price for the company. Ten equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $119.99.

In related news, major shareholder Lilly Endowment Inc sold 205,000 shares of the business’s stock in a transaction dated Tuesday, March 26th. The shares were sold at an average price of $131.41, for a total value of $26,939,050.00. Following the transaction, the insider now directly owns 116,814,018 shares of the company’s stock, valued at approximately $15,350,530,105.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction dated Friday, March 22nd. The stock was sold at an average price of $128.50, for a total transaction of $128,500.00. The disclosure for this sale can be found here. Insiders sold a total of 246,112 shares of company stock worth $31,888,255 over the last three months. 0.11% of the stock is owned by insiders.

Shares of NYSE:LLY opened at $115.24 on Thursday. The company has a current ratio of 1.12, a quick ratio of 0.85 and a debt-to-equity ratio of 5.50. The stock has a market capitalization of $108.94 billion, a P/E ratio of 20.76, a P/E/G ratio of 1.99 and a beta of 0.27. Eli Lilly And Co has a fifty-two week low of $84.64 and a fifty-two week high of $132.13.

Eli Lilly And Co (NYSE:LLY) last issued its quarterly earnings results on Tuesday, April 30th. The company reported $1.33 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.32 by $0.01. The company had revenue of $5.09 billion for the quarter, compared to the consensus estimate of $5.12 billion. Eli Lilly And Co had a net margin of 26.13% and a return on equity of 56.62%. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period in the previous year, the firm earned $1.31 EPS. On average, analysts expect that Eli Lilly And Co will post 5.66 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Monday, June 10th. Investors of record on Friday, May 17th were issued a $0.645 dividend. This represents a $2.58 dividend on an annualized basis and a dividend yield of 2.24%. The ex-dividend date of this dividend was Thursday, May 16th. Eli Lilly And Co’s dividend payout ratio (DPR) is currently 46.49%.

TRADEMARK VIOLATION NOTICE: This report was reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2019/06/13/eli-lilly-and-co-nyselly-shares-sold-by-fort-washington-investment-advisors-inc-oh.html.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

See Also: Understanding the different types of bonds

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply